Compare PPG Industries, Inc. (PPG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Sana Biotechnology Inc — how do they compare? PPG Industries, Inc. trades at $104.82 (market cap $23.44B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: PPG Industries, Inc. is far larger — about 28× Sana Biotechnology Inc's market cap, and PPG Industries, Inc. pays a 2.81% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and Sana Biotechnology Inc for 23 Days on average.
| PPG | SANA | |
|---|---|---|
Market Cap | $23.44B | $836.71M |
Volume | 2,064,777 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $5.92 |
52-Week Low | $94.34 | $2.68 |
Typical Hold Time | 68 Days | 23 Days |
Enterprise Value | $29.31B | $749.96M |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG trades at $105.08, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q2 2026 EPS miss of $2.23 vs. $2.25 expected, though Q1 2026 beat expectations. Fundamentals show a P/E of 15.13, net income margin of 9.57%, and strong cash flow from operations of $1.94B in 2025. Recent news highlights margin pressures in the Automotive Refinish segment but innovation efforts in marine coatings.
The outlook is cautiously optimistic, with a consensus price target of $130 implying 24% upside, supported by 55% analyst buy ratings. Risks include segment-specific weakness and macroeconomic headwinds, but valuation remains reasonable with solid profitability. The stock offers a dividend yield from its upcoming $0.74 payout, appealing for income-focused investors amid ongoing cost management initiatives.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
